Multiple system atrophy (MSA) is a rare neurodegenerative disease that attacks nerve cells in multiple areas of the brain and spinal cord. The disease causes problems with movement, balance and autonomic functions like controlling blood pressure and body temperature. Currently, there is no cure for MSA and treatment focuses on managing symptoms. However, research on potential disease-modifying therapies that may slow or halt disease progression is underway.
The Multiple System Atrophy (MSA) Market is estimated to be valued at USD 148.1 Mn in 2024 and is expected to reach USD 202.3 Mn by 2031, growing at a compound annual growth rate (CAGR) of 4.5% from 2024 to 2031.
Key Takeaways
Chelsea Therapeutics International, Ltd. is a pharmaceutical company focused on developing innovative treatments for neurodegenerative disorders like MSA. Biohaven Pharmaceuticals, Inc. is researching drug candidates like taselisib that may slow MSA disease progression. Sumitomo Dainippon Pharma Co., Ltd. has a pipeline drug for MSA currently in phase 2 clinical trials.
As awareness of MSA increases and more people are diagnosed, demand for effective treatments will rise significantly. The current lack of approved drugs also presents a major opportunity.
Growing aging population also serves to drive the Multiple System Atrophy (MSA) Market growth over the forecast period.
Companies are developing novel drug delivery mechanisms and biomarkers to better understand MSA pathogenesis and evaluate treatment responses. Imaging and fluid biomarkers hold promise to expedite clinical trial enrollment and measure target engagement of experimental therapies.
Market Trends
Increasing Research Collaboration: To effectively tackle this rare disease, research institutions and pharmaceutical companies are joining hands to maximize resources and expertise. Joint ventures allow for sharing of clinical trial networks and biomarker qualification programs.
Focus on Disease-Modifying Therapies: Previously research was focused on symptom management but now focus has shifted to therapies that could potentially halt or slow disease progression. Drugs targeting alpha-synuclein aggregation and neuroinflammation show promise as disease-modifying treatments.
Market Opportunities
Orphan Drug Designation: Regulatory agencies provide incentives like market exclusivity periods for orphan drugs treating rare diseases. This encourages more pharmaceutical investment in MSA therapeutics development.
Unmet Medical Need: Currently there are no approved therapies for addressing the underlying pathophysiology of MSA. The significant unmet need presents lucrative commercial opportunities for treatments demonstrating efficacy in slowing disease progression.
Impact of COVID-19 on Multiple System Atrophy (MSA) Market Growth
The COVID-19 pandemic has significantly impacted the growth of the MSA market. During the initial phase of the pandemic, various restrictions were imposed which limited the hospital visits as well as non-essential diagnostics and treatments. This led to underdiagnosis of MSA cases. The supply chains were also disrupted impacting the availability of diagnostic tools and drugs. With rising COVID cases, the healthcare resources and infrastructure were under immense pressure catering to the COVID patients leaving limited scope for managing other neurological conditions like MSA.
However, with rapid vaccination drives and adaptation to new protocols, the market is recuperating gradually in the post-COVID era. The healthcare systems are endeavoring to handle both COVID and non-COVID cases judiciously. The industry players are investing in R&D to develop new target specific drugs to alter the disease progression. Teleconsultation and home healthcare are evolving to ensure continuity of care. Governments worldwide are supporting both patients and developers to tackle neurodegenerative disorders. While it will take some time for complete recovery, in the long term, emphasis on innovative treatment therapies and decentralized healthcare models will help restore normal market growth trajectory if COVID recedes.
Geographical Regions with Highest MSA Market Value
Currently, North America accounts for the largest share of the global MSA market in terms of value, followed by Europe. This is attributed to the rising prevalence of MSA, growing geriatric population, established healthcare infrastructure and high adoption of advanced treatment options in these regions. Asia Pacific is projected to be the fastest growing regional market owing to increasing awareness, rapidly developing economies and growing healthcare spending in countries like China and India. Meanwhile, Latin America and Middle East & Africa also offer lucrative opportunities for market players to tap unmet needs.
Geographical Region Witnessing Fastest Growth in MSA Market
Asia Pacific region is witnessing the fastest growth in the MSA market currently. This is because of several factors - rising affordability and accessibility to healthcare in the region supported by favourable government initiatives. Also, increasing aging population, growing incidence of neurological disorders, emergence of regional market players catering to domestic needs etc. are driving the Asia Pacific market growth. Moreover, economies like China and India are witnessing rapid urbanization and improved diagnostic capabilities which is further propelling the regional market expansion. The region holds immense growth potential which attracts global players to invest and establish presence to seize the opportunities.
Get More Insights On- Multiple System Atrophy (MSA) Market
Get This Report in Japanese Language: 多系統萎縮症市場
Get This Report in Korean Language: 다중 시스템 위축 시장
About Author:
Ravina Pandya, Content Writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc.
(https://www.linkedin.com/in/ravina-pandya-1a3984191)